Table 2.
Distribution of ever use of menopausal hormone therapy with endometrial cancer tumour-defined characteristics in postmenopausal women.
| TUMOR CHARACTERISTICS | ||||||||
|---|---|---|---|---|---|---|---|---|
| Grade§ Frequency n(%) |
Depth of myometrial invasion Frequency n(%) |
|||||||
| Use of MHT| | 1 | 2 | 3 | other carcinomas | p-value*~ | none/<50% thick | ≥50% thick/through serosa | p-value* |
| Any form of MHT¶ | ||||||||
| No | 150 (31) | 203 (42) | 89 (18) | 44 (9) | 229 (62) | 141 (38) | ||
| Yes | 80 (41) | 78 (40) | 23 (12) | 15 (8) | 0.020 | 119 (77) | 36 (23) | 0.001 |
| Any form of oestrogens¶†∞ | ||||||||
| No | 157 (31) | 208 (42) | 89 (18) | 45 (9) | 238 (62) | 144 (38) | ||
| Yes | 72 (40) | 73 (40) | 23 (13) | 14 (7) | 0.090 | 109 (77) | 33 (23) | 0.002 |
| Oestrogens and Progestins¶∞‡∫Ω | ||||||||
| No | 182 (33) | 228 (41) | 96 (17) | 50 (9) | 272 (63) | 157 (37) | ||
| Yes | 43 (39) | 48 (44) | 13 (12) | 6 (5) | 0.256 | 68 (83) | 14 (17) | 0.001 |
| Oestrogens with cyclic progestins¶∞∫Ω | ||||||||
| No | 186 (32) | 240 (42) | 101 (18) | 50 (9) | 284 (64) | 161 (36) | ||
| Yes | 36 (42) | 36 (42) | 8 (9) | 5 (6) | 0.080 | 54 (86) | 9 (14) | 0.001 |
| Oestrogens with continuous progestins¶∞∫Ω | ||||||||
| No | 209 (34) | 257 (41) | 101 (16) | 52 (8) | 310 (65) | 165 (35) | ||
| Yes | 10 (27) | 17 (46) | 8 (22) | 2 (5) | 0.559 | 23 (79) | 6 (21) | 0.121 |
| Low potency vaginal oestrogens▲ | ||||||||
| No | 198 (34) | 242 (41) | 94 (16) | 50 (9) | 290 (65) | 157 (35) | ||
| Yes | 32 (33) | 39 (40) | 18 (18) | 9 (9) | 0.837 | 58 (74) | 20 (26) | 0.102 |
| Low potency oral oestrogens^ | ||||||||
| No | 175 (32) | 224 (41) | 95 (17) | 52 (10) | 274 (65) | 149 (35) | ||
| Yes | 54 (40) | 57 (42) | 17 (13) | 7 (5) | 0.194 | 73 (72) | 28 (28) | 0.152 |
Endometrioid carcinoma grades1–3 correspond to histological differentiation: well, moderate, and poor, respectively; other carcinomas include: seropapillary carcinoma, clear cell carcinoma, adenoacanthoma, and adenosquamous carcinoma
Ever use of menopausal hormone therapies are not mutually exclusive
p-value: Pearson Chi-squared tests of association between groups
p-value association does not include other carcinomas
Medium potency MHT
Ever use of oestrogens with or without progestins
Conjugated oestrogens; oestradiol; or other synthetic
Use of oestrogens and progestins, cyclic and/or continuous
Cyclic progestins: added to oestrogens for less than 16 days/cycle, mostly for 10–14 days; continuous progestins: added to oestrogens for 19 or more days per cycle, mostly daily
Progesterone-like progestins (17-hydroxy-progesterone derivatives); or testosterone-like progestins (19-nor-testosterone derivatives)
Oestriol 0.5 mg; dienoestrol 0.5 mg; oestradiol 0.25 μg. Daily applications during initial 2–3 weeks of treatment, followed by applications twice per week
1–2 mg daily